SCHEMBL181523

SCHEMBL181523

NCCCCCCNCC(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.69
MAOB P27338 1/20 0.69
LMNA P02545 3/20 0.56
ALOX15 P16050 3/20 0.56
KMT2A Q03164 3/20 0.56
THRB P10828 2/20 0.56
MEN1 O00255 2/20 0.56
RECQL P46063 2/20 0.56
ALDH1A1 P00352 1/20 0.56
PLG P00747 1/20 0.56
SLC6A2 P23975 1/20 0.56
SLC6A3 Q01959 1/20 0.56
CYP2D6 P10635 1/20 0.52
NFKB1 P19838 1/20 0.52
CYP1A2 P05177 3/20 0.50
TSHR P16473 2/20 0.50
BLM P54132 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
CA12 O43570 2/20 0.50
F13A1 P00488 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288829 1.00 MAOA (0.69) MAOAMAOBLMNAALOX15KMT2A
SCHEMBL7700013 0.98 MAOA (0.67) MAOAMAOBLMNAALOX15KMT2A
SCHEMBL163406 0.98 MAOA (0.65) MAOAMAOBLMNAALOX15KMT2A
SCHEMBL11113096 0.95 MAOA (0.63) MAOAMAOBLMNAALOX15KMT2A
SCHEMBL93783 0.91
Dodecylamine SCHEMBL7193288 0.90 MAOA (0.58) MAOAMAOBLMNAALOX15KMT2A
SCHEMBL21492932 0.90 MAOA (0.58) MAOAMAOBLMNAALOX15KMT2A
SCHEMBL7984820 0.89 CYP1A2 (0.56) MAOAMAOBLMNAALOX15KMT2A
SCHEMBL28831589 0.88 MAOA (0.54) MAOAMAOBLMNAALOX15KMT2A
Hydrochloric Acid SCHEMBL16227633 0.88 MAOA (0.54) MAOAMAOBLMNAALOX15KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120077039-A Fusion azines as dynamin-1 like protein inhibitors and uses thereof 安斯泰来工程小分子美国股份有限公司 2025-05-30 CN disclosed
CN-119923385-A Inhibitors of RNA helicase DHX9 and uses thereof 埃克森特治疗公司 2025-05-02 CN disclosed
CN-119855809-A Emopanamide binding protein inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-18 CN disclosed
CN-119731160-A Emopanamide binding protein inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-03-28 CN disclosed
CN-119730848-A Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment 阿尔克姆斯有限公司 2025-03-28 CN disclosed
CN-119731156-A Emopanamide binding protein inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-03-28 CN disclosed
WO-2025038979-A1 COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND/OR TREATMENT OF AMYLOID B PEPTIDE PROTEINOPENIA IN ALZHEIMER'S AND OTHER DISEASES LVIS-Regain LP (US) 2025-02-20 WO disclosed
CN-115836054-B IL4I1 inhibitors and methods of use 默沙东有限责任公司 2024-12-10 CN disclosed
CN-119095845-A Emopanamide binding protein inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2024-12-06 CN disclosed
CN-118993978-A Azaspiroalkane derivatives as inhibitors of stearoyl-CoA desaturase 1 北京药渡医药科技有限公司 2024-11-22 CN disclosed
US-8828413-B2 Peptoid oligomers, pharmaceutical compositions and methods of using the same NEW YORK UNIVERSITY (US) 2014-09-09 US disclosed
US-20120045393-A1 LHRH-II PEPTIDE ANALOGS BRACCO IMAGING SPA (IT) 2012-02-23 US disclosed
US-20120045393-A1 LHRH-II PEPTIDE ANALOGS BRACCO IMAGING SPA (IT) 2012-02-23 US disclosed
US-20120045393-A1 LHRH-II PEPTIDE ANALOGS BRACCO IMAGING SPA (IT) 2012-02-23 US disclosed
US-20120015883-A1 Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-01-19 US disclosed
EP-2401264-A2 PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME New York University (US) 2012-01-04 EP disclosed
WO-2011156003-A2 PEPTOID AND SYNTHETIC OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME NEW YORK UNIVERSITY (US) 2011-12-15 WO disclosed
WO-2010107832-A1 LHRH-II PEPTIDE ANALOGS BRACCO IMAGING SPA (IT) 2010-09-23 WO disclosed
US-20100222255-A1 PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME NEW YORK UNIVERSITY 2010-09-02 US disclosed
WO-2010098843-A2 PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME NEW YORK UNIVERSITY (US) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015883-A1 Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same APP, IAPP, PSEN1 MAOA 2214/4885MAOB 2194/4885LMNA 2282/4885
US-20120045393-A1 LHRH-II PEPTIDE ANALOGS LHCGR, GNRHR, FSHR MAOA 4770/4885MAOB 4480/4885LMNA 4466/4885
US-20100222255-A1 PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME NOD2, VIP, NOD1 MAOA 4240/4885MAOB 3986/4885LMNA 3660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.